{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:23:25Z","timestamp":1773948205087,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Key Project of Precision Medicine of the Wuxi Health Commission","award":["Grant No. J202008"],"award-info":[{"award-number":["Grant No. J202008"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Liver function monitoring is recommended when agomelatine is prescribed, although liver enzymes are not considered predictive biomarkers. Most patients present with acute liver injury, with only a few presenting with levels of liver enzymes that are over 30 times the upper limit of normal. The patient-specific risk factors that are associated with liver injury remain unclear. Thus, this report provides new insights into the mechanism of agomelatine-induced acute hepatocellular injury based on cytochrome P450 family 1 subfamily A member 2 (CYP1A2) polymorphism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We present a case of acute hepatocellular injury in a 75-year-old man who was taking agomelatine at a dose of 50\u200amg\/qn. All hepatitis virus test results were negative. No history of liver disease was observed. As CYP1A2 is the main metabolic enzyme of agomelatine, CYP1A2 AA (rs762551) genetic polymorphism was analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient's transaminases level exceeded the critical value on day 72 after starting oral agomelatine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received intravenous magnesium isoglycyrrhizinate, a liver cell-protecting agent, followed by the withdrawal of agomelatine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>There was an improvement in the levels of the liver enzymes and no subsequent organ dysfunction was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Here, we report a case of acute hepatocellular injury characterized by a very high aspartate aminotransferase level. Periodic liver function testing throughout the treatment period can help in the rapid and appropriate diagnosis of acute liver injury, particularly in the absence of typical clinical manifestations. Agomelatine hepatic toxicity might be related to an idiosyncratic metabolic reaction that depends on individual patient differences. As it is the main metabolic enzyme of agomelatine, CYP1A2 genetic polymorphism may contribute to liver injury by affecting its metabolites.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027736","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T14:07:05Z","timestamp":1636726025000},"page":"e27736","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-6287","authenticated-orcid":false,"given":"Shushan","family":"Wang","sequence":"first","affiliation":[{"name":"The Affiliated Wuxi Mental Health Center of Nanjing Medical University, Department of Pharmacy, Binhu District, Wuxi City, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[{"name":"The Affiliated Wuxi Mental Health Center of Nanjing Medical University, Department of Psychiatry, Binhu District, Wuxi City, Jiangsu Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kankan","family":"Qu","sequence":"additional","affiliation":[{"name":"The Affiliated Wuxi Mental Health Center of Nanjing Medical University, Department of Pharmacy, Binhu District, Wuxi City, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Wuxi Mental Health Center of Nanjing Medical University, Department of Psychiatry, Binhu District, Wuxi City, Jiangsu Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhe","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Affiliated Wuxi Mental Health Center of Nanjing Medical University, Department of Psychiatry, Binhu District, Wuxi City, Jiangsu Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e14099","DOI":"10.1097\/MD.0000000000014099","article-title":"Therapeutic role of melatonin in migraine prophylaxis: a systematic review","volume":"98","author":"Long","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","article-title":"Antidepressant-induced liver injury: a review for clinicians","volume":"171","author":"Voican","year":"2014","journal-title":"Am J Psychiatry"},{"key":"R3-20250504","first-page":"311","article-title":"Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures","volume":"33","author":"Jacquot","year":"2019","journal-title":"Pharmaceut Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1570159X12999140619122914","article-title":"AGM in the treatment of major depressive disorder: an assessment of benefits and risks","volume":"12","author":"Gahr","year":"2014","journal-title":"Curr Neuropharmacol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40263-019-00611-9","article-title":"Risk of acute liver injury in AGM and other antidepressant users in four European countries: a cohort and nested case-control study using Automated Health Data Sources","volume":"33","author":"Pladevall-Vila","year":"2019","journal-title":"CNS Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","article-title":"Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French National Health Insurance Database","volume":"32","author":"Billioti","year":"2018","journal-title":"CNS Drugs"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40263-016-0351-6","article-title":"Characterisation of AGM-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patients","volume":"30","author":"Perlemuter","year":"2016","journal-title":"CNS Drugs"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fpsyt.2020.00380","article-title":"Depression in the elderly consensus statement of the Spanish Psychogeriatric Association","volume":"11","author":"Ag\u00fcera-Ortiz","year":"2020","journal-title":"Front Psychiatry"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2045125319855206","DOI":"10.1177\/2045125319855206","article-title":"What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?","volume":"9","author":"Potm\u011b\u0161il","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jchromb.2015.09.018","article-title":"Development and validation a LC-MS\/MS method for the simultaneous determination of agomelatine and its metabolites, 7-desmethyl-agomelatine and 3-hydroxy-agomelatine in human plasma: Application to a bioequivalence study","volume":"1003","author":"Li","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0928-0987(00)00146-9","article-title":"Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling","volume":"12","author":"Jan","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s43440-020-00151-w","article-title":"The effects of AGM and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat","volume":"72","author":"Haduch","year":"2020","journal-title":"Pharmacol Rep"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0269881119827959","article-title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics","volume":"33","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"J Psychopharmacol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","article-title":"Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene","volume":"24","author":"Eap","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2045125316646064","article-title":"Insomnia and dementia: is AGM treatment helpful? Case report and review of the literature. Ther","volume":"6","author":"Vesile","year":"2016","journal-title":"Adv Psychopharmaco"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2147\/NDT.S167608","article-title":"AGM versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial","volume":"13","author":"Che","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jad.2018.05.060","article-title":"Effect of agomelatine 25\u201350 mg on functional outcomes in patients with major depressive disorder","volume":"238","author":"Kennedy","year":"2018","journal-title":"J Affect Disord"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fphar.2019.00242","article-title":"Sub-acute oral toxicity of a novel derivative of AGM in rats in a sex-dependent manner","volume":"19","author":"Yang","year":"2019","journal-title":"Front Pharmacol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2174\/1389200215666140926155041","article-title":"Safety and tolerability of AGM: focus on hepatotoxicity","volume":"15","author":"Gahr","year":"2014","journal-title":"Curr Drug Metab"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40261-020-00957-9","article-title":"AGM in standard medical practice in depressed patients: results of a 1-year multicentre observational study in France","volume":"40","author":"Gorwood","year":"2020","journal-title":"Clin Drug Investig"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12325-017-0485-z","article-title":"Pooled analysis of four non-interventional studies: effectiveness and tolerability of the antidepressant AGM in daily practice","volume":"34","author":"Laux","year":"2017","journal-title":"Adv Ther"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2016.03.020","article-title":"Characterizing novel metabolic pathways of melatonin receptor agonist AGM using metabolomic approaches","volume":"109","author":"Liu","year":"2016","journal-title":"Biochemical Pharmacol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1358\/dot.2009.45.8.1396673","article-title":"AGM: a novel pharmacological approach to treating depression","volume":"45","author":"Owen","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jms.2020","article-title":"Validated LC-MS\/MS method for quantification of AGM in human plasma and its application in a pharmacokinetic study","volume":"47","author":"Patil","year":"2012","journal-title":"J Mass Spectrom"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5507\/bp.2015.065","article-title":"Quantification of selected antidepressants and antipsychotics in clinical samples using chromatographic methods combined with mass spectrometry: A review (2006-2015)","volume":"160","author":"Sistik","year":"2016","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2125.2011.04076.x","article-title":"Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes","volume":"73","author":"Yang","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/138920009790711805","article-title":"Pharmacogenomics in drug induced liver injury","volume":"10","author":"Andrade","year":"2009","journal-title":"Curr Drug Metab"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jcpt.12118","article-title":"Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers","volume":"39","author":"Song","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41397-017-0011-3","article-title":"The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis","volume":"18","author":"Koonrungsesomboon","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bcp.13902","article-title":"A semiphysiological population pharmacokinetic model of AGM and its metabolites in Chinese healthy volunteers","volume":"85","author":"Xie","year":"2019","journal-title":"Br J Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:15:10Z","timestamp":1746332110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027736"}},"subtitle":["Case report and review of the literature"],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":30,"journal-issue":{"issue":"45","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027736","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"2021-08-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}